Skip to main content

Advertisement

SpringerLink
Log in

Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the therapeutic effects of Jiedu Granules (解毒颗粒), a Chinese medicine (CM) compound, plus Cinobufacini Injection (华蟾素注射液), which was extracted from skin of Bufo bufo gargarizans Cantor, to prevent the recurrence of hepatocellular carcinoma (HCC) after surgical resection.

Methods

In this case-control trial, a total of 120 patients who stayed in Changhai Hospital were enrolled from December 2001 to December 2006. Sixty patients were treated with Jiedu Granules plus Cinobufacini Injection to prevent tumor recurrence after operation (CM group) and 60 patients were treated with transcatheter arterial chemoembolization (TACE) after operation (TACE group). Progression-free survival (PFS) and overall survival (OS) rates were determined to evaluate the therapeutic effects of post-operative management of patients with HCC.

Results

PFS in the CM group was 18.07 months [95% confidence interval (CI): 12.49–23.65] and the 1-, 2-, 3-, 4- and 5-year PFS rates were 61%, 39%, 26%, 22% and 12%, respectively. PFS in the TACE group was 8.03 months (95% CI: 6.63–9.44) and the 1-, 2-, 3-, 4- and 5-year PFS rates were 34%, 11%, 7%, 2% and 0%, respectively. There was significant difference in survival rate between the two groups (P<0.01). The mean survival time (MST) of patients in the CM group was 49.53 months versus 39.90 months of the TACE group. The 1-, 2-, 3-, 4- and 5-year survival rates were 90%, 82%, 80%, 70% and 63%, respectively, in the CM group, and 79%, 70%, 60%, 60% and 36%, respectively, in the TACE group. There was significant difference in survival time between the two groups (P=0.045).

Conclusions

Jiedu Granules plus Cinobufacini Injection, a combination that is commonly used for post-operation management of HCC, can postpone tumor recurrence and metastasis, prolong the survival time and increase the survival rate of post-surgical patients with HCC. However, these findings need to be confirmed in a prospective, randomized controlled trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535–1547.

    Article  PubMed  CAS  Google Scholar 

  3. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–1440.

    Article  PubMed  CAS  Google Scholar 

  4. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322–330.

    Article  PubMed  CAS  Google Scholar 

  5. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181–200.

    Article  PubMed  Google Scholar 

  6. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized clinical trials. Lancet Oncol 2002;3:593–603.

    Article  PubMed  Google Scholar 

  7. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187–196.

    Article  PubMed  Google Scholar 

  8. Ling CQ. Effect and status of traditional Chinese medicine on tumor. Chin J Integr Tradit West Med (Chin) 2007;27:390–391.

    Google Scholar 

  9. Ling CQ. Problems in cancer treatment and major research of integrative medicine. J Chin Integr Med (Chin) 2003;1:168–170.

    Article  Google Scholar 

  10. Wu MC. Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems. J Chin Integr Med (Chin) 2003;1:163–164.

    Article  Google Scholar 

  11. Han KQ, Gu W, Su YH, Huang XQ, Wang X, Ling CQ. Antitumor effects of bufalin on the orthotopic transplantation tumor model of hepatocellular carcinoma in mice. Chin J Exp Surg (Chin) 2004;21:1436–1438.

    Google Scholar 

  12. Su YH, Huang XQ, Zhang DZ, Zhang YY, Xie JM, Ling CQ. HPLC separation and determination of bufadienolide in Cinobufacini Injection. Chin Tradit Patent Med (Chin) 2003;25:24–27.

    Google Scholar 

  13. Su YH, Yin XC, Xie JM, Gao B, Ling CQ. Inhibition effects of three kinds of bufotoxins on human SMMC-7721 and BEL-7402 hepatoma cells lines. Acad J Sec Milit Med Univ 2003;24:393–395.

    CAS  Google Scholar 

  14. Ma YJ, Ma YP. Cinobufacini Injection treatment of advanced primary liver cancer clinical observation. J Liaoning Univ Tradit Chin Med (Chin) 2010;12:123–124.

    Google Scholar 

  15. Zhou X, Yang JK, Zhu LQ, Gao F, Xie RF, Gu XJ. Meta analysis on Cinobufacini injection in hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin J New Drugs Clin Remed (Chin) 2009;9:671–674.

    Google Scholar 

  16. Yang BH, Xia JL. Criteria for diagnosis and staging of primary liver cancer. Cancer Res Prev Treat (Chin) 2002;29:83.

    Google Scholar 

  17. National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 2.2008). National Comprehensive Cancer Network, Inc.

  18. Liu PF, Liu RH, Xu H, Wu MC. Significance of preventive TACE in primary liver cancer after operation. Chin J Hepatobil Surg (Chin) 2005;11:81–82.

    Google Scholar 

  19. Tanaka K, Shimada H, Togo S, Takahashi T, Endo I, Sekido H, et al. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 1999;46:1083–1088.

    PubMed  CAS  Google Scholar 

  20. Liu PF, Liu RH, Xu H, Wu MC. Significance of preventive TACE in primary cancer after operation. Chin J Hepatobil Surg (Chin) 2005;11(2):81–82.

    Google Scholar 

  21. Wu HP, Feng GS. Status quo and prospect of interventional therapy of liver cancer. J Clin Radiol (Chin) 2005;24:273–276.

    Google Scholar 

  22. An FQ, Matsuda M, Fujii H, Matsumoto Y. Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 2000;126:153–160.

    Article  PubMed  CAS  Google Scholar 

  23. Xi T, Shen F, Wu MC. Effect of postoperative prophylactic transcatheter arterial chemoembolization on delaying recurrence in patients with hepatocellular carcinoma. Chin Tumor (Chin) 2005;14:161–163.

    Google Scholar 

  24. Miao CL, Yu QF, Liang HF. Clinical research of Cinobufacini Injection combined with chemotherapeutic in treating patients with advanced non-small cell lung cancer. Chin J Integr Tradit West Med (Chin) 2007;27:657–658.

    Google Scholar 

  25. Hao CL. Cinobufacini Injection in treatment cancer and its advance effects. China Pharmacist (Chin) 2007;10:704–706.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China

    Zhe Chen  (陈 喆), Hong-yun Chen  (陈红云), Qing-bo Lang  (朗庆波), Bai Li  (李 柏), Xiao-feng Zhai  (翟笑枫), Yu-yu Guo  (郭玉玉), Xiao-qiang Yue  (岳小强) & Chang-quan Ling  (凌昌全)

Authors
  1. Zhe Chen  (陈 喆)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong-yun Chen  (陈红云)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing-bo Lang  (朗庆波)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bai Li  (李 柏)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-feng Zhai  (翟笑枫)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu-yu Guo  (郭玉玉)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao-qiang Yue  (岳小强)
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chang-quan Ling  (凌昌全)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chang-quan Ling  (凌昌全).

Additional information

Supported by National Key Technology R&D Program for the 11th Five-Year Plan (No. 2006 BAI04A06)

These authors contributed equally to this work

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Z., Chen, Hy., Lang, Qb. et al. Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial. Chin. J. Integr. Med. 18, 339–344 (2012). https://doi.org/10.1007/s11655-012-1083-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-012-1083-1

Keywords

Search

Navigation